Compare AIRI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | CTXR |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 16.6M |
| IPO Year | N/A | N/A |
| Metric | AIRI | CTXR |
|---|---|---|
| Price | $3.36 | $0.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 287.5K | ★ 1.3M |
| Earning Date | 11-14-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,031,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.53 | $147.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.77 | $0.63 |
| 52 Week High | $4.48 | $3.40 |
| Indicator | AIRI | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 40.03 |
| Support Level | $3.20 | $0.74 |
| Resistance Level | $3.41 | $0.85 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 79.41 | 33.03 |
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.